Evaluate Vantage Homepage

Vantage logo

Biotech’s near-term key catalysts

Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.

Vantage logo

Pepgen aims to overtake Sarepta

Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.

Medtech

Company Events

Interviews

Vantage logo

Pepgen aims to overtake Sarepta

Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.

Vantage logo

T3D puts a bet on Alzheibetes

An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.